Eric Whitman: FDA’s Rejection of RP1 by Replimune
Eric Whitman, System Medical Director, Atlantic Health System Cancer Care at Atlantic Health, shared on X:
“Still thinking about the FDA and its rejection of RP1 by Replimune. Now this via The Wall Street Journal editorial board.
I am not familiar with the rare Barth syndrome. But I know melanoma. I’ve been a researcher on countless melanoma trials. RP1 works, and it works in people who have no other FDA-approved options, whose melanoma has blasted through powerful and often effective treatments like they were water. I’ve seen it myself in patients and talked to others with similar experiences.
Still unsure who made the final, sudden and unexpected decision to deny patients access to this potentially lifesaving drug. I only hope that rationality prevails for our patients and their families.”
More posts featuring FDA.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023